Vivian Altmann

Dr. Vivian Altmann


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 November 2012 in Pharmacogenomics
Verified
Journal Article
Closed access
MRMariana Rieck
Mariana Rieck
ASArtur F. Schumacher-Schuh
Artur F. Schumacher-Schuh
VAVivian Altmann
Vivian Altmann
CFCarolina Lm Francisconi
Carolina Lm Francisconi
PFPaulo Tb Fagundes
Paulo Tb Fagundes
MHMara Hutz
Mara Hutz
Aim: Dyskinesia and motor fluctuation are frequent and serious complications of chronic levodopa therapy in patients with Parkinson’s disease. Since genetic factors could play a role in determining...

29 October 2018 in Journal of Neural Transmission
Verified
Journal Article
Closed access
PDF file
NSNayron Medeiros Soares
Nayron Medeiros Soares
GPGabriela Magalhães Pereira
Gabriela Magalhães Pereira
VAVivian Altmann
Vivian Altmann
RARosa Maria Martins de Almeida
Rosa Maria Martins de Almeida
CRCarlos R. M. Rieder
Carlos R. M. Rieder

29 March 2016 in Pharmacogenomics
Verified
Journal Article
Closed access
VAVivian Altmann
Vivian Altmann
ASArtur F Schumacher-Schuh
Artur F Schumacher-Schuh
MRMariana Rieck
Mariana Rieck
SCSidia M Callegari-Jacques
Sidia M Callegari-Jacques
CRCarlos R. M. Rieder
Carlos R. M. Rieder
MHMara Hutz
Mara Hutz
Aim: Levodopa is first-line treatment of Parkinson's disease motor symptoms but, dose response is highly variable. Therefore, the aim of this study was to determine how much levodopa dose could be explained by biological, pharmacological and genetic factors. Patients & methods: A total of 224 Parkinson's disease patients were genotyped for SV2C and SLC6A3 polymorphisms by allelic discrimination assays. Comedication, demographic and clinical data were also assessed. Results: All variables with p < 0.20 were included in a multiple regression analysis for dose prediction. The final model explained 23% of dose variation (F = 11.54; p < 0.000001). Conclusion: Although a good prediction model was obtained, it still needs to be tested in an independent sample to be validated.

15 April 2015 in Pharmacogenomics
Verified
Journal Article
Closed access
MRMariana Rieck
Mariana Rieck
ASArtur F. Schumacher-Schuh
Artur F. Schumacher-Schuh
SCSidia M Callegari-Jacques
Sidia M Callegari-Jacques
VAVivian Altmann
Vivian Altmann
MMMárcio Schneider Medeiros
Márcio Schneider Medeiros
MHMara Hutz
Mara Hutz
Levodopa is first line treatment of Parkinson's disease (PD). However, its use is associated with the presence of motor fluctuations and dyskinesias. In recent years, adenosine A2A receptor (A2AR) is rising as a therapeutic target for PD. The aim of the present study was to investigate whether ADORA2A is associated with levodopa adverse effects. Two hundred and eight PD patients on levodopa therapy were investigated. rs2298383 and rs3761422 at the ADORA2A gene were genotyped by allelic discrimination assays. A trend for association was observed for both polymorphism and diplotypes with dyskinesia. The present results should be considered as positive preliminary evidence. Further studies are needed to determine the association between ADORA2A and dyskinesia. Original submitted 3 December 2014; Revision submitted 13 February 2015.

1 February 2016 in Neuroscience Letters
Verified
Journal Article
Closed access
VAVivian Altmann
Vivian Altmann
ASArtur F. Schumacher-Schuh
Artur F. Schumacher-Schuh
MRMariana Rieck
Mariana Rieck
SCSidia M. Callegari-Jacques
Sidia M. Callegari-Jacques
CRCarlos R. M. Rieder
Carlos R. M. Rieder
MHMara Hutz
Mara Hutz

15 October 2013 in The Pharmacogenomics Journal
Verified
Journal Article
Closed access
PDF file
ASArtur F. Schumacher-Schuh
Artur F. Schumacher-Schuh
VAVivian Altmann
Vivian Altmann
MRM Rieck
M Rieck
LTL Tovo-Rodrigues
L Tovo-Rodrigues
TMT L Monte
T L Monte
MHMara Hutz
Mara Hutz